What does the evidence say about Glutamine Gut Health Randomized Trial?

Updated July 2026

Quick Answer

Glutamine Gut Health Randomized Trial has evidence relevant to benefits, uncertainty, and practical interpretation, but conclusions should stay close to the cited sources. One representative finding is: 1 2 3 4 5 5 6 7 6 7 Irritable bowel syndrome (IBS) is a chronic disorder of gut–brain interaction characterized by recurrent abdominal pain associated with altered bowel habits, in the absence of identifiable structural abnormalities [].

Key Takeaways

  • 011 2 3 4 5 5 6 7 6 7 Irritable bowel syndrome (IBS) is a chronic disorder of gut–brain interaction characterized by recurrent abdominal pain associated with altered bowel habits, in the absence of identifiable structural abnormalities []. [Šuran Jelena (2026)]
  • 02Early studies reported SIBO in up to 60–78% of IBS cases based on lactulose breath testing [,,], though later investigations using more rigorous methods found lower prevalences (e.g., 4–20%) [,]. [Šuran Jelena (2026)]
  • 03Moreover, increasing evidence implicating the gut microbiota in IBS/SIBO has spurred interest in interventions that modulate microbial communities. [Šuran Jelena (2026)]
  • 04It affects an estimated 5–10% of the global population and is more common in women, imposing a significant burden on quality of life and healthcare resources []. [Šuran Jelena (2026)]
The current Migaku evidence database contains 1 reusable source document for Glutamine Gut Health Randomized Trial. This answer focuses on benefits, uncertainty, and practical interpretation. - 1 2 3 4 5 5 6 7 6 7 Irritable bowel syndrome (IBS) is a chronic disorder of gut–brain interaction characterized by recurrent abdominal pain associated with altered bowel habits, in the absence of identifiable structural abnormalities []. [Šuran Jelena (2026); evidence level 3] - Early studies reported SIBO in up to 60–78% of IBS cases based on lactulose breath testing [,,], though later investigations using more rigorous methods found lower prevalences (e.g., 4–20%) [,]. [Šuran Jelena (2026); evidence level 3] - Moreover, increasing evidence implicating the gut microbiota in IBS/SIBO has spurred interest in interventions that modulate microbial communities. [Šuran Jelena (2026); evidence level 3] - It affects an estimated 5–10% of the global population and is more common in women, imposing a significant burden on quality of life and healthcare resources []. [Šuran Jelena (2026); evidence level 3] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.

Sources

  1. IBS and SIBO: Gut Microbiota, Pathophysiology, and Non-Pharmacological Interventions